Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Leber Congenital Amaurosis (LCA) Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Leber Congenital Amaurosis (LCA) Overview | 8 | 1 |
| Pipeline Products for Leber Congenital Amaurosis (LCA) Comparative Analysis | 9 | 1 |
| Leber Congenital Amaurosis (LCA) Therapeutics under Development by Companies | 10 | 1 |
| Leber Congenital Amaurosis (LCA) Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Leber Congenital Amaurosis (LCA) Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Leber Congenital Amaurosis (LCA) Products under Development by Companies | 15 | 1 |
| Leber Congenital Amaurosis (LCA) Products under Investigation by Universities/Institutes | 16 | 1 |
| Leber Congenital Amaurosis (LCA) Companies Involved in Therapeutics Development | 17 | 6 |
| AmpliPhi Biosciences Corporation | 17 | 1 |
| Applied Genetic Technologies Corporation | 18 | 1 |
| Editas Medicine, Inc. | 19 | 1 |
| ProQR Therapeutics N.V. | 20 | 1 |
| QLT Inc. | 21 | 1 |
| Spark Therapeutics, Inc. | 22 | 1 |
| Leber Congenital Amaurosis (LCA) Therapeutics Assessment | 23 | 9 |
| Assessment by Monotherapy Products | 23 | 1 |
| Assessment by Target | 24 | 2 |
| Assessment by Mechanism of Action | 26 | 2 |
| Assessment by Route of Administration | 28 | 2 |
| Assessment by Molecule Type | 30 | 2 |
| Drug Profiles | 32 | 17 |
| A-001 Drug Profile | 32 | 2 |
| Gene Therapy for Leber Congenital Amaurosis 10 Drug Profile | 34 | 1 |
| Gene Therapy to Activate Retinal Guanylyl Cyclase-1 for Leber Congenital Amaurosis-1 Drug Profile | 35 | 1 |
| Gene Therapy to Activate Retinal Pigment Epithelium 65 for Leber Congenital Amaurosis Drug Profile | 36 | 2 |
| HORARPE-65 Drug Profile | 38 | 1 |
| QR-110 Drug Profile | 39 | 1 |
| voretigene neparvovec Drug Profile | 40 | 4 |
| zuretinol acetate Drug Profile | 44 | 5 |
| Leber Congenital Amaurosis (LCA) Dormant Projects | 49 | 1 |
| Leber Congenital Amaurosis (LCA) Product Development Milestones | 50 | 10 |
| Featured News &Press Releases | 50 | 1 |
| Jun 01, 2016: ProQR s Drug Candidate QR-110 for Leber s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation | 50 | 1 |
| Apr 25, 2016: ProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-110 for LCA10 at the 2016 ARVO Annual Meeting | 50 | 1 |
| May 04, 2015: Penn Study Indicates that Gene Therapy Efficacy for LCA is Dynamic: Improvement is Followed by Decline in Vision | 50 | 2 |
| May 01, 2015: Spark Therapeutics to Have Multiple Presentations at 2015 ARVO Meeting | 52 | 1 |
| Dec 05, 2014: QLT Announces Results From Proof-of-Concept Trial With Oral Synthetic cis-Retinoid (QLT091001) in Adult Subjects With Impaired Dark Adaptation and/or Impaired Low Luminance Vision | 52 | 2 |
| Nov 06, 2014: Spark Therapeutics Receives FDA Breakthrough Therapy Designation for Its Lead Product Candidate, SPK-RPE65 | 54 | 1 |
| Sep 12, 2014: QLT Announces Positive Final Results From Phase 1b Retreatment Trial With Oral Synthetic cis-Retinoid (QLT091001) in Subjects With LCA or RP Due to Mutations in RPE65 or LRAT | 55 | 1 |
| Jul 14, 2014: QLT Announces Publication in The Lancet of Phase 1b Data for QLT091001 in Leber Congenital Amaurosis Due to LRAT or RPE65 Mutations | 56 | 1 |
| May 08, 2014: Spark Therapeutics Scientific Advisor to Deliver Keynote at the Association for Research in Vision and Ophthalmology s 2014 Annual Meeting | 57 | 1 |
| Feb 27, 2014: QLT Announces Positive Preliminary Results From Phase 1b Retreatment Trial of QLT091001 in Subjects With Leber Congenital Amaurosis and Retinitis Pigmentosa Due to Mutations in LRAT or RPE65 | 57 | 1 |
| Jan 14, 2014: Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness | 58 | 2 |
| Appendix | 60 | 2 |
| Methodology | 60 | 1 |
| Coverage | 60 | 1 |
| Secondary Research | 60 | 1 |
| Primary Research | 60 | 1 |
| Expert Panel Validation | 60 | 1 |
| Contact Us | 60 | 1 |
| Disclaimer | 61 | 1 |